Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Allotrope Foundation Reaches First Major Milestone in Development of Laboratory Information Framework and Launch of Partner Network

Published: Sunday, March 30, 2014
Last Updated: Sunday, March 30, 2014
Bookmark and Share
Allotrope Foundation aims to make the intelligent analytical laboratory a reality.

Allotrope Foundation, a consortium of pharmaceutical and biotech companies, has reached the first major milestone in the development of its innovative laboratory information Framework and announced the launch of a partner network to encourage further collaboration.

In just six months, the Foundation has gone from concept to implementation of its first Proof of Concept (PoC) application using the open Framework that will manage analytical data throughout its complete lifecycle using a common set of standard tools.

Allotrope has also established a Partner Network, designed to enable and encourage collaboration with the instrument and software vendor community in developing the Framework.

“The deployment of the first Proof of Concept is a significant milestone on our development roadmap”, said Wolfgang Colsman, CTO of Osthus GmbH and lead architect of the Allotrope Framework. “In about six months of development, we were able to go from an idea to a working implementation.”

Allotrope Foundation aims to make the intelligent analytical laboratory a reality – an automated laboratory where data, methods and hardware components are seamlessly shared between disparate platforms, and where one-click reports can be produced using data generated on any analytical instrument. The Proof of Concept now deployed addresses experiment initiation and data acquisition using instruments from multiple vendors (standard instrument input-output). This PoC also demonstrates the seamless exchange of analytical data between software applications from different vendors. This state-of-the-art data exchange demonstrates several new capabilities, including the simple exchange of data between an Allotrope member and a business partner, for example, a CRO.

“I am really excited to be part of this historic event and of our contribution to bringing the longstanding vision of the intelligent analytical lab one step closer to a reality,” said Janet Cheetham, Executive Director, Analytical Research and Development at Amgen and Board Member of Allotrope. “Seeing the Framework perform as expected in one of our own laboratories validates the core fundamentals of Allotrope’s approach to solving many of the current pain points we are experiencing today with analytical data management in Pharma Biotech and in many other industries that have analytical labs.”

“From the onset of Allotrope Foundation, we’ve been focused on building a sustainable Framework that will enhance how we produce and consume analytical data,” said James Roberts, Senior Scientific Investigator, Analytical Development at GlaxoSmithKline (GSK) and co-lead of the Allotrope Foundation Core Technical Team. “Using the Framework to embed open standards in our labs, running real experiments in 2014, is the first step to enhancing efficiency, facilitating data exchange and enabling automation.”

The successful deployment of a Proof of Concept also triggers the launch of Allotrope’s Partner Network, which is designed to give all software and hardware vendors an opportunity to provide direct feedback to Allotrope Foundation regarding the Framework.

“We took great care to design a Partner Network that enables all interested vendors to provide feedback on the Framework,” said Gordon Hansen, VP Analytical Development, US and Chairman of Allotrope Foundation Board of Directors. “There has been strong interest from the vendor community in working with us, and we are thrilled to open the doors to such a collaboration.”

As part of the Partner Network, Allotrope provides access to pre-release software, documentation, interfaces and test data.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!